Nano flavonoids might aggravate the abnormal expression of IGF1 R in Rat Brain-An alarming note necessitating careful Dose and Route
Keywords:
Nanoflavanoids, Oral and IV delivery, Synaptic plasma membrane, Insulin like growth factor 1 receptor (IGF 1R)Abstract
Recent decades have a greater attention towards the nanoparticles and their therapeutic aspects in human health. Further, nanoparticles of effective active components of herbal extracts are being investigated widely as an alternative medicine. However, the precise data on such aspects are till scarce. In this study we aimed at elucidating the efficacy and safer dose as well routé of nano flavonoids which have been claimed to have neuroprotective role. We used a potential target namely Insulin like growth factor 1 receptor (IGF 1R) of rat brain tissues to evaluate the efficacy as IGF 1R critically involved in neurological homeostasis. We analyzsed the impact of two different doses (50mg & 100mg/kg bw) of crude extract of orange (rich in flavonoids), isolated fraction of flavonoids and nano flavonoids administered in two different routes [oral and Intravenous IV)] on synaptic plasma membrane and on IGF 1R. We inferred that the oral route of extract and nano flavonoids were not detrimental while an alarming influence of IV mode of flavonoids in nano form showing a significant increase in the expression of IGF 1R which is not a desirable in normal rats as it would result in abnormal conditions such as malignancy. In addition, the isolated flavonoids (IV) also showed a significant increase in the expression of IGF 1R in normal rats at the examined doses which also do require attention. The partial and preliminary study stresses the significance of careful designing of nano medicines using naturally occurring and beneficial flavonoids.
References
2. Gwinn MR, Vallyathan V. Nanoparticles: health effects-pros and cons. Environ Health Perspect 2006; 114(12): 1818-25.
3. de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008; 2(6): 1101-13.
4. Hollman PC, Katan MB. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 1999; 37(9-10): 937-42.
5. Subramanian SSAN. Flavonoids of the seeds of Crotalaria .retusa and C. striata. Current Science 1969; 38: 65-68.
6. Yadav S, Sheorain AK, Madan N et al. Esthetics with prosthetics in case of maxillary canine transposition: a clinical report. Nigerian Journal of Clinical Practice 2012; 15(1): 108- 11.
7. Usman H, Abdulrahman F, Usman A. Qualitative phytochemical screening and in vitro antimicrobial effects of methanol stem bark extract of Ficus thonningii (Moraceae). Afr J Tradit Complement Altern Med 2009; 6(3): 289-95.
8. Bello IA, Ndukwe GI, Audu OT et al. A bioactive flavonoid from Pavetta crassipes K. Schum. Org Med Chem Lett
2011; 1(1): 14.
9. Thirumalairaj MPVVK, Durairaj G, Shanmu- gaasokan L et al. Potential antibacterial activity of crude extracts and silver nanoparticles synthesized from Sargassum wightii. International Current Pharmaceutical Journal 2014; 3(10): 322-25.
10. Seethalakshmi ASAS. Phytochemical Synthesis and Preliminary Characterization of Silver Nanoparticles Using Hesperidin. Journal of Nanoscience 2013.
11. Whittaker VP. Thirty years of synaptosome research. J Neurocytol 1993; 22(9): 735-42.
12. Breukel AI, Besselsen E Ghijsen WE. A model system to study release of multiple classes of neurotransmitters. Methods Mol Biol 1997; 72: 33-47.
13. Trojan J, Cloix JF, Ardourel MY et al. Insulin- like growth factor type I biology and targeting in malignant gliomas. Neuroscience 2007; 145(3): 795-811.
14. Scheff SW, Price DA. Alzheimer’s disease- related synapse loss in the cingulate cortex. J Alzheimers Dis 2001; 3(5): 495-505.
15. Scheff SW, Price DA, Sparks DL. Quantitative assessment of possible age-related change in synaptic numbers in the human frontal cortex. Neurobiol Aging 2001; 22(3): 355-65.
16. Yin S, Girnita A, Stromberg T et al. Targeting the insulinlike growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 2010; 12(1): 19-27.
Published
Issue
Section
Copyright (c) 2018 Journal of Advanced Research in NanoScience and NanoTechnology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
